BACKGROUND: trans fatty acid (TFA) intake increases systemic inflammation in healthy persons. However, the effect in patients with established heart disease is unknown. OBJECTIVE: Our aim was to determine whether TFAs are associated with systemic inflammation in patients with established heart disease. DESIGN: Red blood cell membrane TFAs, a biomarker of dietary intake, and inflammatory marker concentrations were ascertained in 86 ambulatory patients with established heart failure. Associations between TFA levels and inflammatory markers were evaluated by linear regression. RESULTS: Mean (+/-SD) TFA levels were 1.8 +/- 0.4% of membrane fatty acids (range: 0.7-2.9%). For each inflammatory marker, associations are presented as the absolute difference and percentage difference from the mean for each 1% higher membrane TFA level. After adjustment for age, sex, body mass index, diabetes, smoking, ejection fraction, New York Heart Association class, ischemic etiology, statin use, and serum glucose, TFA levels were positively associated with interleukin (IL) 1beta (difference from mean: 0.38 pg/mL; percentage difference from mean: 66%; P=0.04), IL-1 receptor antagonist (4033 pg/mL; 297%; P=0.006), IL-6 (9.5 pg/mL; 123%; P=0.006), IL-10 (241 pg/mL; 183%; P=0.02), tumor necrosis factor (TNF) alpha (256 pg/mL; 249%; P=0.02), TNF receptor 1 (537 pg/mL; 41%; P=0.03), TNF receptor 2 (39 242 pg/mL; 247%; P=0.001), monocyte chemoattractant protein 1 (117 pg/mL; 119%; P=0.004), and brain natriuretic peptide (40 pg/mL; 57%; P=0.04). Further adjustments for other patient characteristics did not significantly alter the results. CONCLUSION: TFAs are strongly associated with systemic inflammation in patients with heart disease, which suggests that attention to TFA intake may be important for secondary prevention efforts.
BACKGROUND:trans fatty acid (TFA) intake increases systemic inflammation in healthy persons. However, the effect in patients with established heart disease is unknown. OBJECTIVE: Our aim was to determine whether TFAs are associated with systemic inflammation in patients with established heart disease. DESIGN: Red blood cell membrane TFAs, a biomarker of dietary intake, and inflammatory marker concentrations were ascertained in 86 ambulatory patients with established heart failure. Associations between TFA levels and inflammatory markers were evaluated by linear regression. RESULTS: Mean (+/-SD) TFA levels were 1.8 +/- 0.4% of membrane fatty acids (range: 0.7-2.9%). For each inflammatory marker, associations are presented as the absolute difference and percentage difference from the mean for each 1% higher membrane TFA level. After adjustment for age, sex, body mass index, diabetes, smoking, ejection fraction, New York Heart Association class, ischemic etiology, statin use, and serum glucose, TFA levels were positively associated with interleukin (IL) 1beta (difference from mean: 0.38 pg/mL; percentage difference from mean: 66%; P=0.04), IL-1 receptor antagonist (4033 pg/mL; 297%; P=0.006), IL-6 (9.5 pg/mL; 123%; P=0.006), IL-10 (241 pg/mL; 183%; P=0.02), tumor necrosis factor (TNF) alpha (256 pg/mL; 249%; P=0.02), TNF receptor 1 (537 pg/mL; 41%; P=0.03), TNF receptor 2 (39 242 pg/mL; 247%; P=0.001), monocyte chemoattractant protein 1 (117 pg/mL; 119%; P=0.004), and brain natriuretic peptide (40 pg/mL; 57%; P=0.04). Further adjustments for other patient characteristics did not significantly alter the results. CONCLUSION:TFAs are strongly associated with systemic inflammation in patients with heart disease, which suggests that attention to TFA intake may be important for secondary prevention efforts.
Authors: Sung Nim Han; Lynette S Leka; Alice H Lichtenstein; Lynne M Ausman; Ernst J Schaefer; Simin Nikbin Meydani Journal: J Lipid Res Date: 2002-03 Impact factor: 5.922
Authors: M Rauchhaus; W Doehner; D P Francis; C Davos; M Kemp; C Liebenthal; J Niebauer; J Hooper; H D Volk; A J Coats; S D Anker Journal: Circulation Date: 2000-12-19 Impact factor: 29.690
Authors: Rozenn N Lemaitre; Irena B King; Trivellore E Raghunathan; Rachel M Pearce; Sheila Weinmann; Robert H Knopp; Michael K Copass; Leonard A Cobb; David S Siscovick Journal: Circulation Date: 2002-02-12 Impact factor: 29.690
Authors: Jennifer C Lovejoy; Steven R Smith; Catherine M Champagne; Marlene M Most; Michael Lefevre; James P DeLany; Yvonne M Denkins; Jennifer C Rood; Johannes Veldhuis; George A Bray Journal: Diabetes Care Date: 2002-08 Impact factor: 19.112
Authors: Y Okada; Y Tsuzuki; H Sato; K Narimatsu; R Hokari; C Kurihara; C Watanabe; K Tomita; S Komoto; A Kawaguchi; S Nagao; S Miura Journal: Clin Exp Immunol Date: 2013-12 Impact factor: 4.330
Authors: Stacey A Missmer; Jorge E Chavarro; Susan Malspeis; Elizabeth R Bertone-Johnson; Mark D Hornstein; Donna Spiegelman; Robert L Barbieri; Walter C Willett; Susan E Hankinson Journal: Hum Reprod Date: 2010-03-23 Impact factor: 6.918
Authors: Ashwin N Ananthakrishnan; Hamed Khalili; Gauree G Konijeti; Leslie M Higuchi; Punyanganie de Silva; Charles S Fuchs; Walter C Willett; James M Richter; Andrew T Chan Journal: Gut Date: 2013-07-04 Impact factor: 23.059
Authors: Dariush Mozaffarian; Edmond K Kabagambe; Catherine O Johnson; Rozenn N Lemaitre; Ani Manichaikul; Qi Sun; Millennia Foy; Lu Wang; Howard Wiener; Marguerite R Irvin; Stephen S Rich; Hongyu Wu; Majken K Jensen; Daniel I Chasman; Audrey Y Chu; Myriam Fornage; Lyn Steffen; Irena B King; Barbara McKnight; Bruce M Psaty; Luc Djoussé; Ida Y-D Chen; Jason H Y Wu; David S Siscovick; Paul M Ridker; Michael Y Tsai; Eric B Rimm; Frank B Hu; Donna K Arnett Journal: Am J Clin Nutr Date: 2014-12-10 Impact factor: 7.045
Authors: Eric J Chow; Jill H Simmons; Christian L Roth; K Scott Baker; Paul A Hoffmeister; Jean E Sanders; Debra L Friedman Journal: Biol Blood Marrow Transplant Date: 2010-06-01 Impact factor: 5.742